Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InxMed FAK Inhibitor Ifebemtinib Gets Breakthrough Therapy Status for KRAS NSCLC
Details : IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib (KRAS G12C mutation inhibitor), for the first-line treatment of non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC
Details : InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Escugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
Details : The license agreement provides InxMed with right to use EZWi-Fit® platform for the development of the next generation tumor-associated antigens targeting ADCs. InxMed will have the right for development, manufacturing, and commercialization of these ADC...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Escugen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : D1553
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : InventisBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : D1553 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : D1553
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : InventisBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein alpha, which is investigated for the treatment of hard-to-treat solid tumors.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 29, 2023
Lead Product(s) : OMTX705
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IN10018 Combination Therapy in Previously-treated Solid Tumors
Details : IN10018 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Ifebemtinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : GeneQuantum Healthcare
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : GeneQuantum Healthcare
Deal Size : Undisclosed
Deal Type : Collaboration